Press Releases

YEAR
Toggle Summary Nabriva Therapeutics Announces $38 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , May 29, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered into
View HTML
Toggle Summary Nabriva Therapeutics Receives Positive EU CHMP Opinion for XENLETA™ (lefamulin) for the Treatment of Community-Acquired Pneumonia (CAP)
If approved, XENLETA has the potential to be a first-in-class pleuromutilin antibiotic for the intravenous (IV) and oral treatment of adult patients with CAP in Europe   CHMP opinion supported by robust safety and efficacy data from two global pivotal Phase 3 trials of XENLETA   European Commission
View HTML
Toggle Summary Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference
DUBLIN, Ireland , May 27, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder , Chief Executive Offer at
View HTML
Toggle Summary National Burden of Macrolide-Resistant Streptococcus Pneumoniae in the United States From Blood and Respiratory Tract Cultures Approaches 40 Percent
Large, contemporary, cross-sectional study highlights the urgent need for local epidemiology data to be available to inform empiric antibiotic choices that are concordant with the IDSA/ATS community-acquired pneumonia (CAP) guidelines DUBLIN, Ireland , May 18, 2020 (GLOBE NEWSWIRE) -- Nabriva
View HTML
Toggle Summary Nabriva Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Updates
-Cash runway extended into the fourth quarter of 2020 through judicious resource management- - XENLETA managed care coverage and patient reimbursement continues to strengthen- -Potential value-creating life cycle management for XENLETA initiated via non-dilutive support- -Conference call today at
View HTML
Toggle Summary Nabriva Therapeutics to Present at the BofA Securities 2020 Virtual Health Care Conference
DUBLIN, Ireland , May 11, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder , Chief Executive Offer at
View HTML
Toggle Summary Nabriva Therapeutics to Report First Quarter 2020 Financial Results on May 11, 2020
DUBLIN, Ireland , May 08, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its first quarter financial
View HTML
Toggle Summary XENLETA® (Lefamulin) Treatment Results in a Rapid Time-to-Clinical Response in Hospitalized Patients with Community-Acquired Bacterial Pneumonia (CABP)
Results support Xenleta as an empiric, short-course monotherapy replacement for respiratory fluoroquinolones for treatment of CABP DUBLIN, Ireland , May 05, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development
View HTML
Toggle Summary Centers for Medicare & Medicaid Services Issues Product-Specific J-Code for XENLETA
DUBLIN, Ireland , April 09, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that the Centers for Medicare and Medicaid
View HTML
Toggle Summary Nabriva Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
DUBLIN, Ireland , April 08, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder , Chief Executive Offer at
View HTML

For Media Inquiries

E-mail: PR@nabriva.com


For Investor Relations

E-mail: IR@nabriva.com